These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 17503740)

  • 1. Huntington's disease: pathological mechanisms and therapeutic strategies.
    Ramaswamy S; Shannon KM; Kordower JH
    Cell Transplant; 2007; 16(3):301-12. PubMed ID: 17503740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease.
    McBride JL; Ramaswamy S; Gasmi M; Bartus RT; Herzog CD; Brandon EP; Zhou L; Pitzer MR; Berry-Kravis EM; Kordower JH
    Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9345-50. PubMed ID: 16751280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmaceutical, cellular and genetic therapies for Huntington's disease.
    Handley OJ; Naji JJ; Dunnett SB; Rosser AE
    Clin Sci (Lond); 2006 Jan; 110(1):73-88. PubMed ID: 16336206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Huntington's disease: an update of therapeutic strategies.
    Kumar A; Kumar Singh S; Kumar V; Kumar D; Agarwal S; Rana MK
    Gene; 2015 Feb; 556(2):91-7. PubMed ID: 25447911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on Huntington's disease.
    Berman SB; Greenamyre JT
    Curr Neurol Neurosci Rep; 2006 Jul; 6(4):281-6. PubMed ID: 16822347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Huntington's disease: new frontiers for molecular and cell therapy.
    Melone MA; Jori FP; Peluso G
    Curr Drug Targets; 2005 Feb; 6(1):43-56. PubMed ID: 15720212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospects for neuroprotective therapies in prodromal Huntington's disease.
    Chandra A; Johri A; Beal MF
    Mov Disord; 2014 Mar; 29(3):285-93. PubMed ID: 24573776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The mGluR5 positive allosteric modulator, CDPPB, ameliorates pathology and phenotypic signs of a mouse model of Huntington's disease.
    Doria JG; de Souza JM; Andrade JN; Rodrigues HA; Guimaraes IM; Carvalho TG; Guatimosim C; Dobransky T; Ribeiro FM
    Neurobiol Dis; 2015 Jan; 73():163-73. PubMed ID: 25160573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Animal models of Huntington's disease.
    Ramaswamy S; McBride JL; Kordower JH
    ILAR J; 2007; 48(4):356-73. PubMed ID: 17712222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uncovering the ferroptosis related mechanism of laduviglusib in the cell-type-specific targets of the striatum in Huntington's disease.
    Liu M; Zhao J; Xue C; Yang J; Ying L
    BMC Genomics; 2024 Jun; 25(1):633. PubMed ID: 38918688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The paradigm of Huntington's disease: therapeutic opportunities in neurodegeneration.
    Leegwater-Kim J; Cha JH
    NeuroRx; 2004 Jan; 1(1):128-38. PubMed ID: 15717013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell Replacement Therapy for Huntington's Disease.
    Monk R; Connor B
    Adv Exp Med Biol; 2020; 1266():57-69. PubMed ID: 33105495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Murine Models of Huntington's Disease for Evaluating Therapeutics.
    Kosior N; Leavitt BR
    Methods Mol Biol; 2018; 1780():179-207. PubMed ID: 29856020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dysregulation of synaptic proteins, dendritic spine abnormalities and pathological plasticity of synapses as experience-dependent mediators of cognitive and psychiatric symptoms in Huntington's disease.
    Nithianantharajah J; Hannan AJ
    Neuroscience; 2013 Oct; 251():66-74. PubMed ID: 22633949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transplanted fetal striatum in Huntington's disease: phenotypic development and lack of pathology.
    Freeman TB; Cicchetti F; Hauser RA; Deacon TW; Li XJ; Hersch SM; Nauert GM; Sanberg PR; Kordower JH; Saporta S; Isacson O
    Proc Natl Acad Sci U S A; 2000 Dec; 97(25):13877-82. PubMed ID: 11106399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Huntington's disease and cell therapies: past, present, and future.
    Antoniades CA; Watts C
    Methods Mol Biol; 2013; 1010():19-32. PubMed ID: 23754216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Animal models of Huntington's disease: implications in uncovering pathogenic mechanisms and developing therapies.
    Wang LH; Qin ZH
    Acta Pharmacol Sin; 2006 Oct; 27(10):1287-302. PubMed ID: 17007735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Huntington's disease: From molecular basis to therapeutic advances.
    Krobitsch S; Kazantsev AG
    Int J Biochem Cell Biol; 2011 Jan; 43(1):20-4. PubMed ID: 21056115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulatory Strategies for Huntington's Disease Treatment.
    Colpo GD; Rocha NP; Stimming EF; Teixeira AL
    CNS Neurol Disord Drug Targets; 2017; 16(8):936-944. PubMed ID: 28606048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stem cell therapy and cellular engineering for treatment of neuronal dysfunction in Huntington's disease.
    Choi KA; Hwang I; Park HS; Oh SI; Kang S; Hong S
    Biotechnol J; 2014 Jul; 9(7):882-94. PubMed ID: 24827816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.